אוונקס Izraelis - hebrajų - Ministry of Health

אוונקס

medison pharma ltd - interferon beta 1a 30 mcg/vial - powder for solution for injection - interferon beta-1a - avonex is indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. avonex is also indicated for the treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

אקסטביה Izraelis - hebrajų - Ministry of Health

אקסטביה

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

רבטול Izraelis - hebrajų - Ministry of Health

רבטול

merck sharp & dohme israel ltd - ribavirin - קפסולות - ribavirin 200 mg - ribavirin - ribavirin - rebetol is indicated for the treatment of chronic hepatitis c and must only be used as part of a combination regimen with peginterferon alfa-2b (adults) or interferon alfa-2b (adults). rebetol monotherapy must not be used. there is no safety or efficacy information on the use of rebetol with other forms of interferon (i.e., not alfa-2b).previously untreated (na?ve) patients rebetol is indicated in adult patients :• in combination with peginterferon alfa-2b or interferon alfa-2b , for the treatment of adult patients with chronic hepatitis c, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for serum hcv-rna . additionally, rebetol is indicated , in combination with peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis c ,not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for serum hcv-rna including patients with clinically stable hiv co-infection. pre

WATER - JEL Izraelis - hebrajų - Ministry of Health

water - jel

עמוס גזית בע"מ - כלל האוכלוסיה